NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- In the press release issued on May 5, 2015 by Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) under the same headline, please note that the May 13th presentation falls on a Wednesday, not Thursday as originally stated. The full and corrected release follows:
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Greg Madison, the Company's Chief Executive Officer, will be presenting a company overview, including progress with the commercialization of Auryxia™ (ferric citrate) in the United States, at the Bank of America Merrill Lynch 2015 Health Care Conference, to be held at the Encore at the Wynn in Las Vegas, NV on May 12-14, 2015.
Mr. Madison's presentation will take place on Wednesday, May 13th at 5:00 p.m. PT (8:00 p.m. ET). A live audio webcast of Mr. Madison's presentation will be accessible within the Investor Relations section of the Company's website at http://investors.keryx.com. An archived version of this webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in New York and Boston, is focused on bringing innovative therapies to market for patients with renal disease. The Company launched its first FDA-approved product, Auryxia, in the United States in December 2014. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. For more information about Keryx, please visit www.keryx.com.
CONTACT: Amy Sullivan, Vice President, Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 617.466.3447 E-mail: email@example.com
Source:Keryx Biopharmaceuticals, Inc.